The United States Department of Energy issued a report entitled “Top Value Added Chemicals from Biomass”. The report confirms the $10's of billions market opportunities that exist for innovators able to deliver these high value chemicals in a cost effective manner. The biological production of these chemicals changes the cost structure well beyond the single digit percentages typical of today's chemical industry, up to 50% or even an order of magnitude in cost reduction. As in the biotech industry, perfecting even one of these molecules forms the basis for a paradigm shifting industrial biotechnology corporation.
Kalion is an early stage industrial biotech company that will transform the traditional chemical industry by providing low-cost access to glucaric acid and S-3-hydroxybutyrolactone (3-HBL) using traditional, green, fermentation technology. Glucaric acid and 3-HBL were identified as “Top Value Added Chemicals from Biomass” and multi-billion dollar markets for use of the two chemicals are limited by cost and availability (2004 DOE report).
Our team is composed of a diverse set of individuals with broad and relevant experience.
He formerly worked at McKinsey & Co. and several different startups. While at McKinsey, one of his key assignments was to develop a strategy for a key bioengineered product for a Fortune 500 company. The strategy proved widely successful for the company, and for over a decade, has driven billions in profits. He received his MA in Philosophy, Politics and Economics while studying at Oxford University on a Rhodes Scholarship. He received two S.B.'s from MIT, one in Electrical Engineering and one in Science, Technology and Society. He is a former member of the Massachussets Institute of Technology's board of trustees and Great Lakes Industrial Technology Council (GLITeC) Advisory Board.SEND ME AN EMAIL
Kristala Prather is the Theodore T. Miller Career Development Associate Professor of Chemical Engineering at MIT. She obtained a Bachelor of Science degree in chemical engineering from MIT in 1994, and a Ph.D. degree from the University of California, Berkeley, in 1999. At Berkeley, she worked under the supervision of Prof. Jay D. Keasling on the development of expression vectors for metabolic engineering. Prof. Prather joined the faculty of MIT after 4 years in BioProcess Research and Development at Merck Research Labs (Rahway, NJ), first as a Senior Research Biochemical Engineer and then as a Research Fellow. While at Merck, she worked on projects in the areas of biocatalysis for small molecule transformations, high-yield production of plasmids as DNA vaccines, and mammalian cell line development for production of therapeutic proteins. Prof. Prather’s research interests are centered on the design and assembly of recombinant microorganisms for the production of small molecules, with additional efforts in novel bioprocess design approaches. Research combines the traditions of metabolic engineering with the practices of biocatalysis to expand and optimize the biosynthetic capacity of microbial systems. A particular focus is the elucidation of design principles for the production of unnatural organic compounds within the framework of the burgeoning field of synthetic biology.SEND ME AN EMAIL
Dr. Watson has almost thirty years of experience in the pharmaceutical and biotechnology industries. Dr. Watson is currently the Chief Executive Officer of Estabrook Pharmaceuticals, Inc. He is also an Executive-in-Residence at Oxford Bioscience Partners and serves on the boards of several biotech companies. Most recently, Dr. Watson was Vice President of Business Development at SmartCells, Inc. where he negotiated the sale of the company to Merck & Co. for $500M in upfront and milestone payments. His prior appointments include Chief Business Officer and Executive Vice President at Elixir Pharmaceuticals, Inc., Senior Vice President of Corporate Development at Cubist Pharmaceuticals, Inc. and Senior Vice President, IP and Licensing at Nycomed Amersham plc. (now General Electric Co.) and he previously held a variety of scientific, R&D and business management positions at Nycomed AS, Salutar Inc. and DuPont Pharmaceuticals, Inc. where he invented the brain imaging drug NeuroLite. Dr Watson received his B.Sc. (Hons) from the University of N.S.W. in Sydney, Australia, his Ph.D. in Chemistry from the Australian National University in Canberra, Australia and carried out postdoctoral research in the U.K. and at Harvard University. He also obtained an M.B.A. from Northeastern University in Boston.SEND ME AN EMAIL